171 related articles for article (PubMed ID: 20816930)
1. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.
Siddiqui A; Patwardhan GA; Liu YY; Nazzal S
Int J Pharm; 2010 Nov; 400(1-2):251-9. PubMed ID: 20816930
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES).
Siddiqui A; Gupta V; Liu YY; Nazzal S
Int J Pharm; 2012 Jul; 431(1-2):222-9. PubMed ID: 22562053
[TBL] [Abstract][Full Text] [Related]
3. A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.
Patwardhan GA; Zhang QJ; Yin D; Gupta V; Bao J; Senkal CE; Ogretmen B; Cabot MC; Shah GV; Sylvester PW; Jazwinski SM; Liu YY
PLoS One; 2009 Sep; 4(9):e6938. PubMed ID: 19742320
[TBL] [Abstract][Full Text] [Related]
4. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
[TBL] [Abstract][Full Text] [Related]
5. Solid lipid nanoparticles co-loaded with doxorubicin and α-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models.
Oliveira MS; Aryasomayajula B; Pattni B; Mussi SV; Ferreira LAM; Torchilin VP
Int J Pharm; 2016 Oct; 512(1):292-300. PubMed ID: 27568499
[TBL] [Abstract][Full Text] [Related]
6. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells.
Liu YY; Han TY; Yu JY; Bitterman A; Le A; Giuliano AE; Cabot MC
J Lipid Res; 2004 May; 45(5):933-40. PubMed ID: 14967819
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells.
Miao J; Du YZ; Yuan H; Zhang XG; Hu FQ
Colloids Surf B Biointerfaces; 2013 Oct; 110():74-80. PubMed ID: 23711779
[TBL] [Abstract][Full Text] [Related]
8. α-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles.
Oliveira MS; Mussi SV; Gomes DA; Yoshida MI; Frezard F; Carregal VM; Ferreira LAM
Colloids Surf B Biointerfaces; 2016 Apr; 140():246-253. PubMed ID: 26764108
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
Wang F; Li L; Liu B; Chen Z; Li C
Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
[TBL] [Abstract][Full Text] [Related]
10. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance.
Liu YY; Han TY; Giuliano AE; Hansen N; Cabot MC
J Biol Chem; 2000 Mar; 275(10):7138-43. PubMed ID: 10702281
[TBL] [Abstract][Full Text] [Related]
11. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles.
Baek JS; Cho CW
Int J Pharm; 2015 Jan; 478(2):617-24. PubMed ID: 25510604
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy.
Kang KW; Chun MK; Kim O; Subedi RK; Ahn SG; Yoon JH; Choi HK
Nanomedicine; 2010 Apr; 6(2):210-3. PubMed ID: 20060074
[TBL] [Abstract][Full Text] [Related]
13. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles.
Mussi SV; Silva RC; Oliveira MC; Lucci CM; Azevedo RB; Ferreira LA
Eur J Pharm Sci; 2013 Jan; 48(1-2):282-90. PubMed ID: 23178339
[TBL] [Abstract][Full Text] [Related]
14. Preparation and cytotoxicity of 2-methoxyestradiol-loaded solid lipid nanoparticles.
Guo X; Xing Y; Mei Q; Zhang H; Zhang Z; Cui F
Anticancer Drugs; 2012 Feb; 23(2):185-90. PubMed ID: 22027535
[TBL] [Abstract][Full Text] [Related]
15. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells.
Mussi SV; Sawant R; Perche F; Oliveira MC; Azevedo RB; Ferreira LA; Torchilin VP
Pharm Res; 2014 Aug; 31(8):1882-92. PubMed ID: 24522814
[TBL] [Abstract][Full Text] [Related]
16. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.
Wong HL; Rauth AM; Bendayan R; Manias JL; Ramaswamy M; Liu Z; Erhan SZ; Wu XY
Pharm Res; 2006 Jul; 23(7):1574-85. PubMed ID: 16786442
[TBL] [Abstract][Full Text] [Related]
17. Poly(styrene-alt-maleic anhydride)-based diblock copolymer micelles exhibit versatile hydrophobic drug loading, drug-dependent release, and internalization by multidrug resistant ovarian cancer cells.
Baranello MP; Bauer L; Benoit DS
Biomacromolecules; 2014 Jul; 15(7):2629-41. PubMed ID: 24955779
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer.
Ren F; Chen R; Wang Y; Sun Y; Jiang Y; Li G
Pharm Res; 2011 Apr; 28(4):897-906. PubMed ID: 21184150
[TBL] [Abstract][Full Text] [Related]
19. Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells.
Li PY; Lai PS; Hung WC; Syu WJ
Biomacromolecules; 2010 Oct; 11(10):2576-82. PubMed ID: 20722436
[TBL] [Abstract][Full Text] [Related]
20. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
